{
    "body": "List genes associated with hypolipidemia.", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22247256", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26546829", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24751931", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22062970"
    ], 
    "ideal_answer": [
        "PCSK9\nAPOB \nANGPTL3\nANGPTL4\nMTP"
    ], 
    "exact_answer": [
        [
            "PCSK9"
        ], 
        [
            "APOB"
        ], 
        [
            "ANGPTL3"
        ], 
        [
            "ANGPTL4"
        ], 
        [
            "MTP"
        ]
    ], 
    "type": "list", 
    "id": "58dfd83a6fddd3e83e000003", 
    "snippets": [
        {
            "offsetInBeginSection": 622, 
            "offsetInEndSection": 788, 
            "text": " Conversely familial hypobetalipoproteinemia is caused by inactivation of the PCSK9 gene which increases the number of LDL receptors and decreases plasma cholesterol.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26546829", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 789, 
            "offsetInEndSection": 985, 
            "text": "Mutations in the genes APOB, and ANGPTL3 and ANGPTL4 (that encode angiopoietin-like proteins which inhibit lipoprotein lipase activity) can further cause low levels of apoB containing lipoproteins", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26546829", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 19, 
            "offsetInEndSection": 329, 
            "text": "Several mutations in the apoB, proprotein convertase subtilisin/kexin type 9 (PCSK9), and MTP genes result in low or absent levels of apoB and LDL-cholesterol in plasma, which cause familial hypobetalipoproteinemia and abetalipoproteinemia. Mutations in the ANGPTL3 gene cause familial combined hypolipidemia. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24751931", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 222, 
            "text": "Mutations of the ANGPTL3 gene have been associated with a novel form of primary hypobetalipoproteinemia, the combined hypolipidemia (cHLP), characterized by low total cholesterol and low HDL-cholesterol levels. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22247256", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1189, 
            "offsetInEndSection": 1437, 
            "text": "These results demonstrated that in a cohort of subjects with severe primary hypobetalipoproteinemia the prevalence of ANGPTL3 gene mutations responsible for a combined hypolipidemia phenotype is about 10%, whereas mutations of APOB gene are absent.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22247256", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 142, 
            "offsetInEndSection": 354, 
            "text": "Angptl3 knockout mice have marked hypolipidemia, and heterozygous carriers of ANGPLT3, loss-of-function mutations were found among individuals in the lowest quartile of plasma triglycerides in population studies.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22062970", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1703, 
            "offsetInEndSection": 2022, 
            "text": "Complete ANGPTL3 deficiency caused by loss-of-function mutations of ANGPTL3 is associated with a recessive hypolipidemia characterized by a reduction of apolipoprotein B and apolipoprotein A-I-containing lipoproteins, changes in subclasses of high-density lipoprotein, and reduced cholesterol efflux potential of serum.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22062970", 
            "endSection": "abstract"
        }
    ]
}